Sign in
CompletedNo phase

The Intervention of Psychobiotics in Patients With Anxiety Disorders

Key facts

Who runs it
Mackay Memorial Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
71 people enrolled
Started
1 Aug 2023
Ended
31 Jul 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Heat-treated PS23
  • Placebo
Record updated
5 December 2025

Who can take part

Age
20 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age 20~70 years old
  • Patients perceived that they had anxiety-related complaints, or with any type of anxiety disorders of adjustment disorders referred from the Departments of Psychiatry, Neurology, Internal Medicine, and Family Medicine in Mackay Memorial Hospital
  • Adult GAD-7 ≥ 8 points (to screen for generalized anxiety disorder) or a DSM-5 diagnosis of generalized anxiety disorder (F41.1) or unspecified anxiety disorder (F41.9)
  • Those who are currently under the treatment of selective serotonin reuptake inhibitors (SSRI) will only be included if their SSRI treatment has been stable or has not been changed for 4 weeks

Who cannot take part

  • Have taken antibiotics or are receiving antibiotic treatment within one month
  • Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy)
  • Patients with chronic psychiatric diseases who are currently taking drugs to treat acute diseases, organic brain diseases, or newly diagnosed or changed drugs within one month
  • Those who are receiving parenteral nutrition
  • Past or current patients with inflammatory bowel disease
  • Those with a history of cancer
  • Those who are allergic to lactic acid bacteria products
  • Have used probiotic products in powder, capsule or tablet form within two weeks (excluding yogurt, Yakult and other related foods)
  • Patients with severe depression (Patient Health Questionnaire-9 (PHQ-9) ≧ 20 points), or possible neurocognitive impairments (Mini-Mental States Examination (MMSE)<20), or those that had suicidal ideation noted on item 9 from PHQ-9
  • Those who are evaluated by the principal investigator to be unsuitable to participate in the research

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigators designed this double blind randomized controlled study and will recruit 120 patients 20 to 65 years old, with DSM-5 generalized anxiety disorder or unspecified anxiety disorder. After clinical symptoms and psychological evaluation and blood sampling, a semi-structural interview delivered by a psychiatrist will be established to confirm the DSM-5 diagnosis. The participants will be randomly assigned to the Lactobacillus paracasei PS23 psychotropic probiotic or placebo group. Blood and stool samples will be obtained after consent. The samples will be tested for biochemistry, inflammation index, cytokines, intestinal osmotic pressure, or gut permeability, and a Fitbit fitness watch will be given to measure changes in sleep.

The 2 groups in the trial

  • Heat-treated PS23Treatment being tested

    Lactobacillus paracasei PS23 heat-treated

  • PlaceboPlacebo, for comparison

    microcrystalline cellulose

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-blind Randomized Controlled Trial Investigating Associations of Microbiota, Serum Total Antioxidant Capacity and Sleep or Psychiatric Symptoms Before and After the Intake of Psychobiotic Lactobacillus Paracasei
Record updated
5 December 2025